Products Brentuximab vedotin is commercially available as a powder for the preparation of an infusion solution (Adcetris). It has been approved in many countries since 2013. Structure and properties Brentuximab vedotin is an anti-CD30 antibody-drug conjugate, a recombinant chimeric lgG1 antibody conjugated to the cytotoxic agent monomethylauristatin E (MMAE, C39H67N5O7, Mr = 718.0 g/mol). It … Brentuximab Vedotin
Products Diazepam is commercially available in tablet, drop, solution for injection, and enema form (Valium, generic). It has been approved in many countries since 1962. In 2020, a diazepam nasal spray was released in the United States. Diazepam was developed by Leo Sternbach at Hoffmann-La Roche as the second member of the benzodiazepine group. Structure … Diazepam: Drug Effects, Side Effects, Dosage and Uses
Products Osimertinib was approved in the United States in 2015 and in the EU and Switzerland in 2016 in film-coated tablet form (Tagrisso). Structure and properties Osimertinib exists in the drug product as osimertinib mesilate (C28H33N7O2 – CH4O3S, Mr = 596 g/mol). It is a methylindole, aniline and pyrimidine derivative. Effects Osimertinib (ATC L01XE35) has … Osimertinib
Products Fostemsavir was approved in the United States in 2020 in sustained-release (ER) tablet form (Rukobia). Fostemsavir is the first agent in this drug class. Structure and properties Fostemsavir (C25H26N7O8P, Mr = 583.5 g/mol) is a prodrug. It is present in the drug as fostemsavirtromethamine, which is biotransformed in the body to the active metabolite … Fostemsavir
Products Tezacaftor was approved in the US and EU in 2018 and in many countries in 2019 in fixed combination with previously registered ivacaftor in film-coated tablet form (Symdeko). In 2020, a fixed combination with tezacaftor, elexacaftor, and ivacaftor was approved (Trikafta). Structure and properties Tezacaftor (C26H27F3N2O6, Mr = 520.5 g/mol) exists as a white … Tezacaftor
Products Tucatinib was approved in the United States and many countries in 2020 in film-coated tablet form (Tukysa). Structure and properties Tucatinib (C26H24N8O2, Mr = 480.5 g/mol) Effects Tucatinib has antitumor and antiproliferative properties. The effects are due to inhibition of HER2 tyrosine kinase. The half-life is approximately 8.5 hours. Indications In combination with trastuzumab … Tucatinib
Products Lansoprazole is commercially available in the form of capsules as meltable tablets (Agopton, generics). It has been approved in many countries since 1993. Structure and properties Lansoprazole (C16H14F3N3O2S, Mr = 369.4 g/mol) is a benzimidazole and pyridine derivative. It exists as a white to brownish-white, odorless, crystalline powder that is practically insoluble in water. … Lansoprazole
Products Simeprevir was approved in capsule form in the United States in 2013, in the EU in 2014, and in many countries in 2015 (Olysio). Structure and properties Simeprevir (C38H47N5O7S2, Mr = 749.9 g/mol) is present in the drug product as simeprevir sodium. The macrocyclic molecule contains a sulfonamide moiety, which may cause adverse effects … Simeprevir
Products Pomalidomide is commercially available in the form of hard capsules (Imnovid). It has been approved in many countries since 2014. It has been registered in the EU and the United States since 2013. Structure and properties Pomalidomide (C13H11N3O4, Mr = 273.2 g/mol) is an amino derivative of thalidomide and a racemate. It is also … Pomalidomide
Products Clarithromycin is commercially available as film-coated tablets, sustained-release tablets, oral suspension, and powder for solution for infusion (Klacid, generics). It has been approved in many countries since 1990. Clarithromycin should not be confused with ciprofloxacin. Structure and properties Clarithromycin (C38H69NO13, Mr = 747.96 g/mol) exists as a white crystalline powder that is practically insoluble … Clarithromycin
